TrialCurveMesenchymal stromal cells for steroid-resistant acute GVHD: reconstructed Kaplan–Meier curves
Reduced morbidity and mortality of cGVHD in patients who received treatment with mesenchymal stromal cells for steroid-resistant aGVHD: long-term follow-up of a randomized phase 3 trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Exp Hematol Oncol. 2025 Jul 9;14:95. doi: 10.1186/s40164-025-00687-8 |
|---|---|
| DOI | 10.1186/s40164-025-00687-8 |
| Registry | NCT02241018 |
| Phase | Phase 2, Phase 3 |
| Conditions | Acute Graft-versus-host Disease |
| Interventions | CD25 monoclonal antibody, calcineurin inhibitors, MSCs |
| Sponsor | Nanfang Hospital, Southern Medical University |
| Enrolment | 200 |
| Source licence | Figure published under CC BY 4.0 |
Overall survival
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: MSC group not reached; Control group 18.9 months. Survival at 18 months: MSC group 64%; Control group 51%. Hazard ratio MSC group vs Control group 0.62 (95% CI 0.42–0.94).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| MSC group | 99 | 40 | not reached |
| Control group | 99 | 57 | 18.9 |
- MSC group vs Control group: reconstructed HR 0.62 (95% CI 0.42–0.94)
Landmark survival (reconstructed)
| Time | MSC group | Control group |
|---|---|---|
| 6 mo | 68.7% | 62.6% |
| 12 mo | 65.7% | 53.5% |
| 18 mo | 63.6% | 51.5% |
| 24 mo | 63.6% | 47.3% |
| 36 mo | 61.6% | 46.3% |
| 48 mo | 61.6% | 42.6% |
| 60 mo | 60.3% | 41.2% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.63, reconstructed 0.624 pass
cGVHD-free, relapse-free survival (CRFS)
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: MSC group 10.6 months; Control group 5.3 months. Survival at 18 months: MSC group 41%; Control group 27%. Hazard ratio MSC group vs Control group 0.66 (95% CI 0.48–0.92).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| MSC group | 99 | 65 | 10.6 |
| Control group | 99 | 78 | 5.3 |
- MSC group vs Control group: reconstructed HR 0.66 (95% CI 0.48–0.92)
Landmark survival (reconstructed)
| Time | MSC group | Control group |
|---|---|---|
| 6 mo | 58.6% | 49.5% |
| 12 mo | 47.4% | 34.3% |
| 18 mo | 41.2% | 27.0% |
| 24 mo | 39.2% | 24.9% |
| 36 mo | 35.0% | 21.8% |
| 48 mo | 35.0% | 20.4% |
| 60 mo | 33.6% | 20.4% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.67, reconstructed 0.664 pass
Cumulative incidence of leukemia relapse
From figure panel C · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Cumulative incidence at 18 months: MSC group 10%; Control group 16%. Hazard ratio MSC group vs Control group 0.82 (95% CI 0.38–1.81).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| MSC group | 99 | 12 | not reached |
| Control group | 99 | 13 | not reached |
- MSC group vs Control group: reconstructed HR 0.82 (95% CI 0.38–1.81)
Cumulative incidence (reconstructed)
| Time | MSC group | Control group |
|---|---|---|
| 6 mo | 8.6% | 9.7% |
| 12 mo | 9.8% | 12.3% |
| 18 mo | 9.8% | 15.7% |
| 24 mo | 9.8% | 15.7% |
| 36 mo | 12.9% | 15.7% |
| 48 mo | 12.9% | 15.7% |
| 60 mo | 14.7% | 15.7% |
Checks against the published figure
- hazard ratio (direction inferred): printed 1.24, reconstructed 1.21 pass
Non-relapse mortality (NRM)
From figure panel D · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Cumulative incidence at 18 months: MSC group 27%; Control group 36%. Hazard ratio MSC group vs Control group 0.68 (95% CI 0.42–1.11).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| MSC group | 99 | 28 | not reached |
| Control group | 99 | 38 | not reached |
- MSC group vs Control group: reconstructed HR 0.68 (95% CI 0.42–1.11)
Cumulative incidence (reconstructed)
| Time | MSC group | Control group |
|---|---|---|
| 6 mo | 24.9% | 27.3% |
| 12 mo | 24.9% | 36.3% |
| 18 mo | 27.1% | 36.3% |
| 24 mo | 27.1% | 39.0% |
| 36 mo | 27.1% | 39.0% |
| 48 mo | 28.5% | 42.4% |
| 60 mo | 30.1% | 42.4% |
Checks against the published figure
- hazard ratio (direction inferred): printed 1.54, reconstructed 1.47 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Related trials
- CPT-MM301: Overall survival; Progression-free survival (Independent Assessment Committee)
- CEPHEUS: Overall survival; Progression-free survival
- ADMYRE: Overall survival; Progression-free survival with PD confirmation by investigator's assessm
- CLL12: Event-free survival (EFS); Overall survival (OS)
- Acalabrutinib vs chlorambucil + rituximab in CLL (Asian phase 3): BICR-assessed duration of response; BICR-assessed progression-free survival; Overall survi
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials